Ars pharmaceuticals files for approval of neffy® in canada and the united kingdom on behalf of licensing partner alk-abellÓ a/s

Canada and united kingdom represent two of the largest markets within the alk portfolio with plans to expand filings of neffy (epinephrine nasal spray) 2 mg in other key global regions

ALK Ratings Summary

ALK Quant Ranking